Peptide Education
Tirzepatide
A dual GIP and GLP-1 receptor agonist used for type 2 diabetes and weight management.
Clinical services are not available yet. GetPeptides has not launched medical visits, prescriptions or pharmacy delivery in any state. Nothing you do here enrolls you in treatment.
Regulatory status
At least one branded product containing this substance is FDA-approved for a defined use in a defined population. Compounded versions of the same active ingredient are not themselves FDA-approved, are not reviewed by the FDA before marketing, and are not confirmed by the FDA to have the same safety or effectiveness as the approved brand.
This page is editorial content written by the GetPeptides team from the publicly available regulatory sources cited below. It has not been reviewed or approved by a qualified independent clinician or pharmacist, and it is not medical advice.
Educational information only — not medical advice. GetPeptides does not sell, prescribe or dispense this substance. A consultation never guarantees a prescription.
FDA-approved products
Mounjaro (type 2 diabetes); Zepbound (chronic weight management and obstructive sleep apnea in certain adults).
Regulatory notes
Approved only for labeled indications. Compounded tirzepatide is not FDA-approved and has not been reviewed by the FDA for safety, effectiveness or quality.
Risks and limitations
Labeling includes gastrointestinal effects, pancreatitis, gallbladder disease and a boxed warning about thyroid C-cell tumors.
Sources
- FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — editorial source list 2026-10-14
- DailyMed: Tirzepatide labeling — editorial source list 2026-10-14
Ask about this page
The assistant is temporarily unavailable. For questions about Tirzepatide, please see the published information on this page, or contact a licensed clinician via the "Find a Licensed Clinician" directory.